Filtered By:
Management: Funding
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 373 results found since Jan 2013.
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
Publication date: Available online 5 December 2017 Source:The Lancet Author(s): Martin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, Zonghui Hu, Galina Yamshchikov, Ro Shauna Rothwell, Nina Berkowitz, Floreliz Mendoza, Jamie G Saunders, Laura Novik, Cynthia S Hendel, LaSonji A Holman, Ingelise J Gordon, Josephine H Cox, Srilatha Edupuganti, Monica A McArthur, Nadine G Rouphael, Kirsten E Lyke, Ginny E Cummings, Sandra Sitar, Robert T Bailer, Bryant M Foreman, Katherine Burgomaster, Rebecca S Pelc, David N Gordon, Christina R DeMaso, Kimberly A Dowd, Carolyn Laurencot, Richard M Schwartz, John R Mascola, Barney S Gr...
Source: The Lancet - December 6, 2017 Category: General Medicine Source Type: research
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials
Publication date: Available online 5 December 2017 Source:The Lancet Author(s): Kayvon Modjarrad, Leyi Lin, Sarah L George, Kathryn E Stephenson, Kenneth H Eckels, Rafael A De La Barrera, Richard G Jarman, Erica Sondergaard, Janice Tennant, Jessica L Ansel, Kristin Mills, Michael Koren, Merlin L Robb, Jill Barrett, Jason Thompson, Alison E Kosel, Peter Dawson, Andrew Hale, C Sabrina Tan, Stephen R Walsh, Keith E Meyer, James Brien, Trevor A Crowell, Azra Blazevic, Karla Mosby, Rafael A Larocca, Peter Abbink, Michael Boyd, Christine A Bricault, Michael S Seaman, Anne Basil, Melissa Walsh, Veronica Tonwe, Daniel F Hoft, Ste...
Source: The Lancet - December 6, 2017 Category: General Medicine Source Type: research
AUSTRI and VESTRI LABA Safety studies subgroup analysis of asthma exacerbations and SAEs comparing FSC and FP by ICS dose
Conclusion: At each ICS dose, the reduction in risk (FSC/FP) of an asthma exacerbation remains favorable, and the overall number of SAEs was low and comparable between FSC and FP.Funding: GSK (NCT01475721, NCT01462344)
Source: European Respiratory Journal - December 6, 2017 Category: Respiratory Medicine Authors: Raphiou, I., Kral, K., Brealey, N., Prillaman, B., Emmett, A., Baidoo, C., Mancuso, M., Pascoe, S. Tags: Allergy and immunology Source Type: research
Trials show inactivated Zika virus vaccine is safe and immunogenic
(NIH/National Institute of Allergy and Infectious Diseases) The investigational Zika purified inactivated virus (ZPIV) vaccine was well-tolerated and induced an immune response in participants, according to initial results from three Phase 1 clinical trials. Scientists at the Walter Reed Army Institute of Research (WRAIR) are developing the vaccine and leading one of the trials. WRAIR also is co-funding the trials with the National Institute of Allergy and Infectious Diseases, part of NIH. The results will appear in The Lancet.
Source: EurekAlert! - Infectious and Emerging Diseases - December 4, 2017 Category: Infectious Diseases Source Type: news
Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial
Publication date: Available online 1 November 2017 Source:The Lancet Author(s): Olivier Varenne, Stéphane Cook, Georgios Sideris, Sasko Kedev, Thomas Cuisset, Didier Carrié, Thomas Hovasse, Philippe Garot, Rami El Mahmoud, Christian Spaulding, Gérard Helft, José F Diaz Fernandez, Salvatore Brugaletta, Eduardo Pinar-Bermudez, Josepa Mauri Ferre, Philippe Commeau, Emmanuel Teiger, Kris Bogaerts, Manel Sabate, Marie-Claude Morice, Peter R Sinnaeve Background Elderly patients regularly receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of double antiplatelet therapy (DAPT). The ai...
Source: The Lancet - November 2, 2017 Category: General Medicine Source Type: research
Mortality rate for people with lupus remains higher than U.S. rate overall
FINDINGSWhile the mortality rate in the United States have declined over the past four decades, UCLA researchers found that the mortality rate for people with lupus has not declined as much as it has for the population overall.The researchers found that among people with lupus, mortality rates are still higher for black people than for other ethnicities; rates for women are higher than those of men; and those in the South were higher than for other regions of the U.S. Mortality rates for people with lupus were affected by where they lived.BACKGROUNDLupus is a chronic disease in which the immune system attacks the body ’s...
Source: UCLA Newsroom: Health Sciences - November 1, 2017 Category: Universities & Medical Training Source Type: news
Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study
Publication date: Available online 1 October 2017 Source:The Lancet HIV Author(s): Krista L Dong, Amber Moodley, Douglas S Kwon, Musie S Ghebremichael, Mary Dong, Nasreen Ismail, Zaza M Ndhlovu, Jenniffer M Mabuka, Daniel M Muema, Karyn Pretorius, Nina Lin, Bruce D Walker, Thumbi Ndung'u Background HIV incidence among young women in sub-Saharan Africa remains high and their inclusion in vaccine and cure efforts is crucial. We aimed to establish a cohort of young women detected during Fiebig stage I acute HIV infection in whom treatment was initiated immediately after diagnosis to advance research in this high-risk group. ...
Source: The Lancet HIV - October 2, 2017 Category: Infectious Diseases Source Type: research
Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial
Publication date: Available online 27 September 2017 Source:The Lancet Global Health Author(s): Ranjeeta Thomas, Ronelle Burger, Abigail Harper, Sarah Kanema, Lawrence Mwenge, Nosivuyile Vanqa, Nomtha Bell-Mandla, Peter C Smith, Sian Floyd, Peter Bock, Helen Ayles, Nulda Beyers, Deborah Donnell, Sarah Fidler, Richard Hayes, Katharina Hauck Background The life expectancy of HIV-positive individuals receiving antiretroviral therapy (ART) is approaching that of HIV-negative people. However, little is known about how these populations compare in terms of health-related quality of life (HRQoL). We aimed to compare HRQoL betwee...
Source: The Lancet Global Health - September 28, 2017 Category: International Medicine & Public Health Source Type: research
Erratum to: Allergen immunotherapy for allergic asthma: protocol for a systematic review
Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is not acknowledged. This section should be corrected to the below:FundingEAACI and the BM4SIT project (Grant Number 601763) in the European Union ’s Seventh Framework Programme FP7.
Source: Clinical and Translational Allergy - September 15, 2017 Category: Allergy & Immunology Source Type: research
Erratum to: Allergen immunotherapy for insect venom allergy: protocol for a systematic review
Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is not acknowledged. This section should be corrected to the below:FundingEAACI and the BM4SIT project (Grant Number 601763) in the European Union ’s Seventh Framework Programme FP7.
Source: Clinical and Translational Allergy - September 15, 2017 Category: Allergy & Immunology Source Type: research
Erratum to: Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review
Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is not acknowledged. This section should be corrected to the below:FundingEAACI and the BM4SIT project (Grant Number 601763) in the European Union ’s Seventh Framework Programme FP7.
Source: Clinical and Translational Allergy - September 15, 2017 Category: Allergy & Immunology Source Type: research
Erratum to: Allergen immunotherapy for IgE-mediated food allergy: protocol for a systematic review
Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is not
acknowledged. This section should be corrected to the below:FundingEAACI and the BM4SIT project (Grant Number 601763) in the European Union ’s Seventh Framework Programme
FP7.
Source: Clinical and Translational Allergy - September 15, 2017 Category: Allergy & Immunology Source Type: research
Aradigm lands NIH grant for inhaled, liposomal products
Aradigm Corp. (NSDQ:ARDM) said today that the National Institute of Allergy and Infectious Diseases and the NIH awarded the company a grant to study the treatment of pulmonary non-tuberculous mycobacteria infections with Aradigm’s inhaled liposomal ciprofloxacin products, Linhaliq and Lipoquin.
The two-year grant is worth approximately $972,000, according to the Hayward, Calif.-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post Aradigm lands NIH grant for inhaled, liposomal products appeared first on MassDevice.
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Pharmaceuticals Respiratory Wall Street Beat Aradigm Corp. Source Type: news
Chikungunya Vaccine Trials Begin
A phase 1 and 2 clinical trial of anexperimental vaccineagainst the viral disease chikungunya has begun enrolling a planned 180 healthy adult volunteers aged 18 to 45 years with funding by the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine, known as MV-CHIKV, is a recombinant live-attenuated measles vaccine virus expressing chikungunya proteins that induce antibody production.
Source: JAMA - July 25, 2017 Category: General Medicine Source Type: research
Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study
Publication date: Available online 18 July 2017 Source:The Lancet HIV Author(s): Renee Heffron, R Scott McClelland, Jennifer E Balkus, Connie Celum, Craig R Cohen, Nelly Mugo, Elizabeth Bukusi, Deborah Donnell, Jairam Lingappa, James Kiarie, Tina Fiedler, Matthew Munch, David N Fredricks, Jared M Baeten Background Daily oral tenofovir-based pre-exposure prophylaxis (PrEP) is high efficacious for HIV prevention among women with high adherence. However, the effect of abnormal vaginal microbiota on PrEP efficacy is of concern. We investigated whether bacterial vaginosis modified the efficacy of oral PrEP. Methods We used pro...
Source: The Lancet HIV - July 19, 2017 Category: Infectious Diseases Source Type: research
